| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.8M | +12.0% | +282.1% |
| SG&A Expense | $2.0M | +36.1% | +4.4% |
| Operating Income | -$11.8M | -15.4% | -165.0% |
| Net Income | -$11.6M | -14.5% | -224.8% |
| EPS (Basic) | -$0.24 | +17.2% | -177.4% |
| EPS (Diluted) | -$0.24 | +17.2% | -177.4% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $15.4M | +241.4% | -28.5% |
| Short-term Investments | $33K | +0.0% | +2.1% |
| Current Assets | $21.5M | +125.6% | -12.5% |
| Total Assets | $21.5M | +125.6% | -12.5% |
| Current Liabilities | $12.2M | +24.3% | +363.4% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$18.8M | — | — |
| Financing Cash Flow | $20.9M | — | — |
| $12.3M |
| +24.0% |
| -28.8% |
| Stockholders' Equity | $9.2M | +2501.4% | +26.3% |